{"id":"butacaine","rwe":[{"pmid":"17983735","year":"2008","title":"Absorption-excipient-pH classification gradient maps: sparingly soluble drugs and the pH partition hypothesis.","finding":"","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","studyType":"Clinical Study"},{"pmid":"17245653","year":"2007","title":"Solubility-excipient classification gradient maps.","finding":"","journal":"Pharmaceutical research","studyType":"Clinical Study"},{"pmid":"17053953","year":"2006","title":"PAMPA - excipient classification gradient map.","finding":"","journal":"Pharmaceutical research","studyType":"Clinical Study"},{"pmid":"12174527","year":"2002","title":"Managing patients with local anesthetic complications using alternative methods.","finding":"","journal":"Pennsylvania dental journal","studyType":"Clinical Study"},{"pmid":"10195347","year":"1999","title":"Involvement of phospholipase A2 activation in anthrax lethal toxin-induced cytotoxicity.","finding":"","journal":"Cell biology and toxicology","studyType":"Clinical Study"}],"tags":[{"label":"butacaine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sodium channel alpha subunits; brain (Types I, II, III)","category":"target"},{"label":"SCN1A","category":"gene"},{"label":"SCN2A","category":"gene"},{"label":"SCN3A","category":"gene"},{"label":"Active","category":"status"},{"label":"Bladder muscle dysfunction - overactive","category":"indication"},{"label":"Increased Urinary Frequency","category":"indication"},{"label":"Neurogenic bladder","category":"indication"},{"label":"Urge incontinence of urine","category":"indication"},{"label":"Urgent desire to urinate","category":"indication"},{"label":"Anesthetics","category":"pharmacology"},{"label":"Anesthetics, Local","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"contraindications":["Angle-closure glaucoma","Atony of colon","Benign prostatic hyperplasia","Bladder outflow obstruction","Chronic heart failure","Conduction disorder of the heart","Disease of liver","Disorder of coronary artery","Drowsy","Gastric retention","Gastroesophageal reflux disease","Gastrointestinal hypomotility","Gastrointestinal obstruction","Hiatal hernia","Hypertensive disorder","Hyperthyroidism","Kidney disease","Myasthenia gravis","Paralytic ileus","Retention of urine","Severe chronic ulcerative colitis","Sinus tachycardia","Toxic megacolon","Ulcerative colitis"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BUTACAINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:59:31.449387+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:59:37.203986+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BUTACAINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:59:37.588415+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL129529/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:59:38.302993+00:00"}},"allNames":"butyn","offLabel":[],"synonyms":["butacaine","butelline","butyn","butacaine sulfate"],"timeline":[],"brandName":"Butyn","ecosystem":[{"indication":"Bladder muscle dysfunction - overactive","otherDrugs":[{"name":"darifenacin","slug":"darifenacin","company":"Warner Chilcott Llc"},{"name":"fesoterodine","slug":"fesoterodine","company":"Pfizer"},{"name":"mirabegron","slug":"mirabegron","company":"Apgdi"},{"name":"oxybutynin","slug":"oxybutynin","company":""}],"globalPrevalence":null},{"indication":"Increased Urinary Frequency","otherDrugs":[{"name":"darifenacin","slug":"darifenacin","company":"Warner Chilcott Llc"},{"name":"fesoterodine","slug":"fesoterodine","company":"Pfizer"},{"name":"flavoxate","slug":"flavoxate","company":""},{"name":"oxybutynin","slug":"oxybutynin","company":""}],"globalPrevalence":null},{"indication":"Neurogenic bladder","otherDrugs":[{"name":"oxybutynin","slug":"oxybutynin","company":""}],"globalPrevalence":null},{"indication":"Urge incontinence of urine","otherDrugs":[{"name":"darifenacin","slug":"darifenacin","company":"Warner Chilcott Llc"},{"name":"fesoterodine","slug":"fesoterodine","company":"Pfizer"},{"name":"oxybutynin","slug":"oxybutynin","company":""},{"name":"solifenacin","slug":"solifenacin","company":"Astellas"}],"globalPrevalence":null},{"indication":"Urgent desire to urinate","otherDrugs":[{"name":"darifenacin","slug":"darifenacin","company":"Warner Chilcott Llc"},{"name":"fesoterodine","slug":"fesoterodine","company":"Pfizer"},{"name":"flavoxate","slug":"flavoxate","company":""},{"name":"oxybutynin","slug":"oxybutynin","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Sodium channel alpha subunits; brain (Types I, II, III)","novelty":"First-in-class","targets":[{"gene":"SCN1A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 1 subunit alpha"},{"gene":"SCN2A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 2 subunit alpha"},{"gene":"SCN3A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 3 subunit alpha"}],"modality":"Small Molecule","drugClass":"butacaine","explanation":"","oneSentence":"","technicalDetail":"Butyn targets sodium channel alpha subunits (Types I, II, III) in the brain, modulating their activity to regulate bladder function."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3050","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BUTACAINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:09:02.590893","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:59:39.934287+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"articaine","drugSlug":"articaine","fdaApproval":"2000-04-03","patentExpiry":"Mar 27, 2039","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"bepridil","drugSlug":"bepridil","fdaApproval":"1990-12-28","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"brompheniramine","drugSlug":"brompheniramine","fdaApproval":"1957-08-23","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"chlorphenamine","drugSlug":"chlorphenamine","fdaApproval":"1950-08-15","relationship":"same-target"},{"drugName":"chlorpromazine","drugSlug":"chlorpromazine","fdaApproval":"1957-09-18","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"cinchocaine","drugSlug":"cinchocaine","fdaApproval":"","relationship":"same-target"},{"drugName":"cyproheptadine","drugSlug":"cyproheptadine","fdaApproval":"1961-10-17","genericCount":31,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"desipramine","drugSlug":"desipramine","fdaApproval":"1964-11-20","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"dicycloverine","drugSlug":"dicycloverine","fdaApproval":"1950-05-11","relationship":"same-target"},{"drugName":"diltiazem","drugSlug":"diltiazem","fdaApproval":"1982-11-05","genericCount":38,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"butacaine","indications":{"approved":[{"name":"Bladder muscle dysfunction - overactive","source":"DrugCentral","snomedId":236633002,"regulator":"FDA"},{"name":"Increased Urinary Frequency","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Neurogenic bladder","source":"DrugCentral","snomedId":398064005,"regulator":"FDA"},{"name":"Urge incontinence of urine","source":"DrugCentral","snomedId":87557004,"regulator":"FDA"},{"name":"Urgent desire to urinate","source":"DrugCentral","snomedId":75088002,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"articaine","brandName":"articaine","genericName":"articaine","approvalYear":"2000","relationship":"same-target"},{"drugId":"bepridil","brandName":"bepridil","genericName":"bepridil","approvalYear":"1990","relationship":"same-target"},{"drugId":"brompheniramine","brandName":"brompheniramine","genericName":"brompheniramine","approvalYear":"1957","relationship":"same-target"},{"drugId":"chlorphenamine","brandName":"chlorphenamine","genericName":"chlorphenamine","approvalYear":"1950","relationship":"same-target"},{"drugId":"chlorpromazine","brandName":"chlorpromazine","genericName":"chlorpromazine","approvalYear":"1957","relationship":"same-target"},{"drugId":"cinchocaine","brandName":"cinchocaine","genericName":"cinchocaine","approvalYear":"","relationship":"same-target"},{"drugId":"cyproheptadine","brandName":"cyproheptadine","genericName":"cyproheptadine","approvalYear":"1961","relationship":"same-target"},{"drugId":"desipramine","brandName":"desipramine","genericName":"desipramine","approvalYear":"1964","relationship":"same-target"},{"drugId":"dicycloverine","brandName":"dicycloverine","genericName":"dicycloverine","approvalYear":"1950","relationship":"same-target"},{"drugId":"diltiazem","brandName":"diltiazem","genericName":"diltiazem","approvalYear":"1982","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000147564","NDDF":"001373","UNII":"Z84S23CGJJ","VUID":"4019434","CHEBI":"CHEBI:94820","VANDF":"4019434","INN_ID":"381","RXNORM":"133044","UMLSCUI":"C0006466","chemblId":"CHEMBL129529","ChEMBL_ID":"CHEMBL129529","DRUGBANK_ID":"DB11502","PUBCHEM_CID":"2480","SNOMEDCT_US":"373532002","SECONDARY_CAS_RN":"149-15-5","MESH_SUPPLEMENTAL_RECORD_UI":"C073325"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":51,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"2008 Jan","pmid":"17983735","title":"Absorption-excipient-pH classification gradient maps: sparingly soluble drugs and the pH partition hypothesis.","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences"},{"date":"2007 Mar","pmid":"17245653","title":"Solubility-excipient classification gradient maps.","journal":"Pharmaceutical research"},{"date":"2006 Nov","pmid":"17053953","title":"PAMPA - excipient classification gradient map.","journal":"Pharmaceutical research"},{"date":"2002 May-Jun","pmid":"12174527","title":"Managing patients with local anesthetic complications using alternative methods.","journal":"Pennsylvania dental journal"},{"date":"1999 Feb","pmid":"10195347","title":"Involvement of phospholipase A2 activation in anthrax lethal toxin-induced cytotoxicity.","journal":"Cell biology and toxicology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:59:39.934287+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}